ARS Pharmaceuticals (SPRY) Other Non-Current Assets (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Other Non-Current Assets data on file, last reported at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets fell 15.27% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 million (down 15.27% YoY), and the FY2025 full-year result was $2.8 million, down 10.53% from the prior year.
• Other Non-Current Assets eased to $2.7 million in Q1 2026, from $2.8 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $3.1 million in Q1 2025 to a low of $21000.0 in Q4 2023.
• A 5-year average of $2.2 million and a median of $2.8 million in 2025 frame the typical range for Other Non-Current Assets.
• Across the five-year window, Other Non-Current Assets sank 99.29% in 2023 and soared 14728.57% in 2024, its largest moves.
• Tracing SPRY's Other Non-Current Assets over 5 years: stood at $3.0 million in 2022, then slumped by 99.29% to $21000.0 in 2023, then soared by 14728.57% to $3.1 million in 2024, then decreased by 10.53% to $2.8 million in 2025, then dropped by 4.77% to $2.7 million in 2026.
• Business Quant data shows SPRY's Other Non-Current Assets at $2.7 million in Q1 2026, $2.8 million in Q4 2025, and $2.9 million in Q3 2025.